基于利益相关视阈下我国药品价格治理实证分析

An Empirical Analysis of Drug Price Control in China Based on Stakeholder Theory

药品治理是医疗卫生保障体制改革的关键,也是近年来医改工作的重点。《"十三五"深化医药卫生体制改革规划》中,着重提出取消药品加成以推进药品价格朝着可及性、公平性方向发展。然而近年来"药价高、看病贵"问题依旧存在,部分药品零售价高于成本十倍以上,药品价格矛盾依旧尖锐。基于利益相关者理论,分析药品价格相关利益主体,发现政府主导的政策管制对药价治理已无明显积极作用,应放开管制发挥市场机制在资源配置中的决定性作用,并通过提高医生待遇,减少医院医生的双向垄断优势减少道德风险;同时,由于患者信息知识等多重不足容易发生羊群效应,不仅会加剧药价攀升,还阻碍其接受药品服务的公平可及性,应加速药品信息公开平台建设。

Abstract Drug administration is the key point of health care system, and it is key of health reform in recent years. In 〈 13th five -year plan for deepening reform of medical and health care system 〉 report, the key point is make drug prices ac- cessibility and equity. However, in recent years, the problem of ＂high drug price and expensive care＂ still exists, and some drugs are ten times higher than it costs, and the price of drugs contradiction is still sharp. Based on stakeholder theory, analyze the re- lated interest subjects, found government- led policy regulation of drug prices has no obvious positive effect, should let go of the control, to bring into decisive role of market mechanism in allocation of resources, and by increasing the doctor treatment, reduce hospital doctors two -way monopoly advantage, reducing the risk of moral hazard; At the same time, patient lack of information knowledge, not only exacerbate drug prices climb, also restrict its fair accept pharmaceutical service accessibility, should speed up the construction of pharmaceutical information public platform.